SHLT — SHL Telemedicine Share Price
Last trade - 00:00- $39.92m
- $40.45m
- $57.08m
- 70
- 75
- 26
- 58
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.59 | ||
| Price to Tang. Book | 2.45 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.71 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -9.68% | ||
| Return on Equity | -12.3% | ||
| Operating Margin | -15.16% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 41.88 | 40.16 | 49.58 | 59 | 57.08 | 66.37 | 80.28 | 3.16% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -40.18 | -94.79 | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
SHL Telemedicine Ltd (SHL) is an Israel-based company engaged in developing and marketing personal telemedicine solutions, with a focus on cardiovascular and related diseases. Personal telemedicine is the transmission of medical data by an individual, from a remote location, to a medical call center through telecommunication networks. SHL’s platform offers solutions to subscribing patients, health insurance companies, hospitals, clinics, physicians and other health care providers. Its solutions for healthcare professionals include: CHF monitoring service that supports patients suffering from Congestive Heart Failure; COPD monitoring service that supports patients suffering from Chronic Obstructive Pulmonary Disease, and Readmission Solutions for reducing heart-related readmissions. Its consumers' solutions include Cardiac Monitoring Service.
Directors
- Yariv Alroy NEC (61)
- Erez Nachtomy CEO (59)
- Yossi Vadnagra CFO
- Yoni Dagan CTO
- Ralf Bork OTH
- Linus Drop OTH
- Erez Alroy NED (59)
- Amir Lerman NED
- Elon Shalev NED (70)
- Yehoshua Abramovich NID
- Dvora Kimhi NID
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- November 7th, 1986
- Public Since
- November 15th, 2000
- No. of Employees
- 448
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 16,391,382
- Address
- Yigal Alon 90, TEL AVIV-YAFO, 67891
- Web
- https://www.shl-telemedicine.com
- Phone
- +972 35612212
- Auditors
- Ernst & Young Global
Similar to SHLT
ADVANCED BIOMED
NASDAQ Capital Market
IMEI Technology Health
NASDAQ Capital Market
Akanda
NASDAQ Capital Market
Astrana Health
NASDAQ Capital Market
Avalon Globocare
NASDAQ Capital Market
FAQ
As of Today at 23:13 UTC, shares in SHL Telemedicine are trading at $2.05. This share price information is delayed by 15 minutes.
Shares in SHL Telemedicine last closed at $2.05 and the price had moved by -67.46% over the past 365 days. In terms of relative price strength the SHL Telemedicine share price has underperformed the S&P500 Index by -68.92% over the past year.
The overall consensus recommendation for SHL Telemedicine is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreSHL Telemedicine does not currently pay a dividend.
SHL Telemedicine does not currently pay a dividend.
SHL Telemedicine does not currently pay a dividend.
To buy shares in SHL Telemedicine you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $2.05, shares in SHL Telemedicine had a market capitalisation of $39.92m.
Here are the trading details for SHL Telemedicine:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: SHLT
Based on an overall assessment of its quality, value and momentum SHL Telemedicine is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in SHL Telemedicine is $11.77. That is 474.37% above the last closing price of $2.05.
Analysts covering SHL Telemedicine currently have a consensus Earnings Per Share (EPS) forecast of -$0.28 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like SHL Telemedicine. Over the past six months, its share price has underperformed the S&P500 Index by -34.32%.
As of the last closing price of $2.05, shares in SHL Telemedicine were trading -41.58% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The SHL Telemedicine PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.05.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
SHL Telemedicine's management team is headed by:
- Yariv Alroy - NEC
- Erez Nachtomy - CEO
- Yossi Vadnagra - CFO
- Yoni Dagan - CTO
- Ralf Bork - OTH
- Linus Drop - OTH
- Erez Alroy - NED
- Amir Lerman - NED
- Elon Shalev - NED
- Yehoshua Abramovich - NID
- Dvora Kimhi - NID